



Wellmark Blue Cross and Blue Shield is an Independent Licensee of the Blue Cross and Blue Shield Association.

## DRUG POLICY

# Promacta (eltrombopag)

### NOTICE

This policy contains information which is clinical in nature. The policy is not medical advice. The information in this policy is used by Wellmark to make determinations whether medical treatment is covered under the terms of a Wellmark member's health benefit plan. Physicians and other health care providers are responsible for medical advice and treatment. If you have specific health care needs, you should consult an appropriate health care professional. If you would like to request an accessible version of this document, please contact customer service at 800-524-9242.

### BENEFIT APPLICATION

Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions may apply. Benefits may vary based on contract, and individual member benefits must be verified. Wellmark determines medical necessity only if the benefit exists and no contract exclusions are applicable. This medical policy may not apply to FEP. Benefits are determined by the Federal Employee Program.

### DESCRIPTION

The intent of the policy is to provide coverage consistent with product labeling, FDA guidance, standards of medical practice, evidence-based drug information, and/or published guidelines. The indications below including FDA-approved indications and compendial uses are considered covered benefits provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

#### FDA-Approved Indications

1. Treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy
2. Treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy
3. First-line treatment of severe aplastic anemia in adult and pediatric patients 2 years and older in combination with standard immunosuppressive therapy
4. Treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy

#### Compendial Use

1. MYH9-related disease with thrombocytopenia
2. Myelodysplastic syndromes, for lower risk disease in patients with severe or refractory thrombocytopenia following disease progression or no response to hypomethylating agents, immunosuppressive therapy, or clinical trial
3. Myelodysplastic syndromes, in combination with equine anti-thymocyte globulin with or without cyclosporine, for treatment of lower risk disease in select patients (generally  $\leq 60$  years old and with  $\leq 5\%$  marrow blasts, or those with hypocellular marrows, PNH clone positivity, or STAT-3 mutant cytotoxic T-cell clones) with clinically relevant thrombocytopenia or neutropenia

## POLICY

### Documentation

Submission of the following information is necessary to initiate the prior authorization review:

1. Chronic or persistent immune thrombocytopenia: pretreatment and current platelet counts
2. Aplastic anemia continuation of therapy: current platelet counts

### Exclusions

Coverage will not be provided for members with the following exclusion:

- Concomitant use of Promacta with other thrombopoietin receptor agonists (e.g., Nplate, Doptelet, Mulpleta) or with spleen tyrosine kinase inhibitors (e.g., Tavalisse)

### Prescriber Specialties

1. For diagnosis of persistent or chronic thrombocytopenia, severe aplastic anemia, MYH9-related disease with thrombocytopenia and myelodysplastic syndromes, this medication must be prescribed by or in consultation with a hematologist or oncologist.
2. For diagnosis of hepatitis C, this medication must be prescribed by or in consultation with a hepatologist, gastroenterologist, or infectious disease specialist.

### Criteria for Initial Approval

#### **A. Chronic or Persistent Immune Thrombocytopenia (ITP)**

Authorization of 6 months may be granted for treatment of chronic or persistent ITP when ALL of the following criteria are met:

1. Inadequate response or intolerance to prior therapy with corticosteroids, immunoglobulins, or splenectomy
2. Untransfused platelet count at any point prior to the initiation of the requested medication is less than  $30 \times 10^9/L$  OR  $30 \times 10^9/L$  to  $50 \times 10^9/L$  with symptomatic bleeding (e.g., significant mucous membrane bleeding, gastrointestinal bleeding or trauma) or risk factors for bleeding (see Section VII)

#### **B. Thrombocytopenia associated with Chronic Hepatitis C**

Authorization of 6 months may be granted to members who are prescribed Promacta for the initiation and maintenance of interferon-based therapy for the treatment of thrombocytopenia associated with chronic hepatitis C.

#### **C. Aplastic Anemia**

1. Authorization of 6 months may be granted for first-line treatment of severe aplastic anemia when Promacta will be used in combination with standard immunosuppressive therapy (e.g., horse antithymocyte globulin (h-ATG) and cyclosporine).
2. Authorization of 6 months may be granted for treatment of aplastic anemia which had an insufficient response to immunosuppressive therapy.

#### **D. MYH9-related disease with thrombocytopenia**

Authorization of 12 months may be granted to members with thrombocytopenia associated with MYH9-related disease.

#### **E. Myelodysplastic Syndromes**

1. Authorization of 12 months may be granted for treatment of myelodysplastic syndromes with severe or refractory thrombocytopenia when both of the following criteria are met:
  - a. Member has lower risk disease defined as Revised International Prognostic Scoring System (IPSS-R) (Very Low, Low, Intermediate), International Prognostic Scoring System (IPSS) (Low/Intermediate-1), WHO classification-based Prognostic Scoring System (WPSS) (Very Low, Low, Intermediate).

- b. Member has severe or refractory thrombocytopenia following disease progression or no response to hypomethylating agents (such as azacitidine and decitabine), immunosuppressive therapy, or clinical trial.
2. Authorization of 12 months may be granted for treatment of myelodysplastic syndromes when all of the following criteria are met:
  - a. Member has lower risk disease defined as Revised International Prognostic Scoring System (IPSS-R) (Very Low, Low, Intermediate), International Prognostic Scoring System (IPSS) (Low/Intermediate-1), WHO classification-based Prognostic Scoring System (WPSS) (Very Low, Low, Intermediate).
  - b. Member has clinically relevant thrombocytopenia or neutropenia.
  - c. Promacta will be used in combination with equine anti-thymocyte globulin.

#### Continuation of Therapy

##### **A. Chronic or Persistent ITP**

1. Authorization of 3 months may be granted to members with current platelet count less than  $50 \times 10^9/L$  for whom the platelet count is not sufficient to prevent clinically important bleeding and who have not received a maximal Promacta dose for at least 4 weeks.
2. Authorization of 12 months may be granted to members with current platelet count less than  $50 \times 10^9/L$  for whom the current platelet count is sufficient to prevent clinically important bleeding.
3. Authorization of 12 months may be granted to members with current platelet count of  $50 \times 10^9/L$  to  $200 \times 10^9/L$ .
4. Authorization of 12 months may be granted to members with current platelet count greater than  $200 \times 10^9/L$  to less than or equal to  $400 \times 10^9/L$  for whom Promacta dosing will be adjusted to achieve a platelet count sufficient to avoid clinically important bleeding.

##### **B. Thrombocytopenia associated with Chronic Hepatitis C**

Authorization of 6 months may be granted to members who are continuing to receive interferon-based therapy.

##### **C. Aplastic Anemia**

1. Authorization of up to 16 weeks total may be granted to members with current platelet count less than  $50 \times 10^9/L$  who have not received appropriately titrated therapy with Promacta for at least 16 weeks.
2. Authorization of up to 16 weeks total may be granted to members with current platelet count less than  $50 \times 10^9/L$  who are transfusion-independent.
3. Authorization of 12 months may be granted to members with current platelet count of  $50 \times 10^9/L$  to  $200 \times 10^9/L$ .
4. Authorization of 12 months may be granted to members with current platelet count greater than  $200 \times 10^9/L$  to less than or equal to  $400 \times 10^9/L$  for whom Promacta dosing will be adjusted to achieve and maintain an appropriate target platelet count.

##### **D. MYH9-related disease with thrombocytopenia**

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

##### **E. Myelodysplastic Syndromes**

Authorization of 12 months may be granted for continued treatment of myelodysplastic syndromes in members who experience benefit from therapy (e.g., increased platelet counts, decreased bleeding events, reduced need for platelet transfusions).

Promacta (eltrombopag) is considered **not medically necessary** for members who do not meet the criteria set forth above.

### Dosing and Administration

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

#### **A. Persistent or chronic ITP**

- Initiate at 50 mg once daily for most adult and pediatric patients 6 years and older and at 25 mg once daily for pediatric patients aged 1 to 5 years.
- Dose reductions are needed for patients of Asian ancestry or those with hepatic impairment.
- Adjust to maintain platelet count greater than or equal to  $50 \times 10^9/L$ .
- Do not exceed 75 mg per day.

#### **B. Chronic Hep C-associated thrombocytopenia**

- Initiate at 25 mg once daily. Adjust to achieve target platelet count required to initiate antiviral therapy.
- Do not exceed a daily dose of 100 mg.

#### **C. First-line severe aplastic anemia**

- Initiate once daily at 2.5 mg/kg (in pediatric patients aged 2 to 5 years old), 75 mg (pediatric patients aged 6 to 11 years old), or 150 mg for patients aged 12 years and older concurrently with standard immunosuppressive therapy.
- Reduce initial dose in patients of Asian ancestry or those with hepatic impairment.
- Modify dosage for toxicity or elevated platelet counts.

#### **D. Refractory severe aplastic anemia**

- Initiate at 50 mg once daily for most patients.
- Reduce initial dose in patients with hepatic impairment or patients of Asian ancestry.
- Adjust to maintain platelet count greater than or equal to  $50 \times 10^9/L$ .
- Do not exceed 150 mg per day.

### Quantity Limits

Medication Name	Quantity Limit
Promacta (eltrombopag) 12.5 mg packet for oral administration	90 packets per 30 days
Promacta (eltrombopag) 25 mg packet for oral administration	90 packets per 30 days
Promacta (eltrombopag) 12.5 mg tablet for oral administration	30 tablets per 30 days
Promacta (eltrombopag) 25 mg tablet for oral administration	90 tablets per 30 days
Promacta (eltrombopag) 50 mg tablet for oral administration	90 tablets per 30 days
Promacta (eltrombopag) 75 mg tablet for oral administration	60 tablets per 30 days

### Appendix

Examples of risk factors for bleeding (not all inclusive)

- Undergoing a medical or dental procedure where blood loss is anticipated
- Comorbidity (e.g., peptic ulcer disease, hypertension)
- Mandated anticoagulation therapy
- Profession (e.g., construction worker) or lifestyle (e.g., plays contact sports) that predisposes member to trauma

## **PROCEDURES AND BILLING CODES**

**To report provider services, use appropriate CPT\* codes, Alpha Numeric (HCPCS level 2) codes, Revenue codes, and/or ICD diagnostic codes.**

## **REFERENCES**

1. Promacta [package insert]. Research Triangle Park, NC: GlaxoSmithKline; October 2021.
2. Pecci A, Gresele P, Klersy C, et al. Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. *Blood*. 2010;116(26):5832-7.
3. The NCCN Drugs & Biologics Compendium® © 2020 National Comprehensive Cancer Network, Inc. <https://www.nccn.org>. Accessed June 15, 2022.

4. The NCCN Clinical Practice Guidelines in Oncology® Myelodysplastic Syndrome (Version 3.2022). © 2020 National Comprehensive Cancer Network, Inc. <https://www.nccn.org>. Accessed June 15, 2022.
5. Nuenert C, Terrel DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. *Blood Adv* 2019;3(23):3829–3866.
6. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. *Blood Adv* 2019;3(22): 3780–3817.
7. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. *Blood*. 2010;115(2):168-186.
8. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. *Blood*. 2009;113(11):2386-2393.
9. Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. *N Engl J Med*. 2012;367(1):11-19.
10. Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. *N Engl J Med* 2017;376:1540-1550.

## POLICY HISTORY

**Policy #:** 05.01.73

**Original Effective Date:** May 17, 2023

**Reviewed:**

**Revised:**

**Current Effective Date:** May 17, 2023